PULM

Pulmatrix, Inc. (PULM) - 10-K Summary for Fiscal Year Ended December 31, 2025

Business Context and Reporting Period

Pulmatrix, Inc. is a biopharmaceutical company focused on developing inhaled therapeutic products using its proprietary iSPERSE™ dry powder delivery technology. The reporting period covers the fiscal year ended December 31, 2025. The company is currently a "virtual company" with no physical facilities and only two full-time employees engaged in administrative activities. Its primary strategic focus is the pending merger with Cullgen Inc. and the monetization of its existing clinical assets (PUR3100, PUR1800, and PUR1900), for which development has been paused.

Key Financial Metrics

Note: The filing text does not provide specific data on debt or liquidity ratios beyond cash balances. The company has no material off-balance sheet arrangements.

Material Changes Versus Prior Period

• Revenue Decline: Revenue dropped to zero in 2025 from $7.8 million in 2024. The 2024 revenue was derived from the Cipla Agreement regarding the PUR1900 program, which was fully wound down in 2024.
• Expense Reduction: Total operating expenses decreased by approximately $12.4 million. R&D expenses fell by $7.1 million due to the termination of the majority of R&D staff following the MannKind Transaction and the completion of the PUR1900 wind-down. G&A expenses decreased by $2.7 million, primarily due to reduced employment costs, partially offset by merger-related expenses.
• One-Time Loss Elimination: The 2024 period included a $2.6 million loss on the MannKind Transaction (disposal of assets and lease assignment), which did not recur in 2025.
• Asset Disposition: The company transitioned to a virtual model, assigning its Bedford facility lease and transferring equipment to MannKind Corporation in 2024.

Guidance, Outlook, and Risks

Merger with Cullgen: The company's future operations are highly dependent on the consummation of the Merger with Cullgen Inc. Stockholders approved the merger in June 2025. Closing is subject to conditions including Nasdaq listing approval and approval from the China Securities Regulatory Commission (CSRC), which has not yet been received as of the filing date. If the merger fails, the board may pursue dissolution and liquidation.

Asset Monetization: Development of product candidates PUR3100 (migraine), PUR1800 (COPD), and PUR1900 (ABPA) is paused. The company is actively seeking opportunities to monetize these assets through licensing or sale.

Liquidity: Management believes existing cash resources ($4.1 million) are sufficient to fund operations for at least 12 months following the filing date. However, continued development of product candidates would require significant additional capital, which may not be available on favorable terms.

Key Risks:

• Failure to obtain CSRC approval for the Merger.
• Inability to monetize clinical assets or secure additional funding if the Merger fails.
• Significant dilution to existing shareholders upon Merger completion (current shareholders expected to own ~3.6% of the combined entity).
• Limitations on the use of Net Operating Loss (NOL) carryforwards due to potential ownership changes.

Investor Verification Checklist

• Merger Status: Verify the current status of the CSRC approval and any updates regarding the "End Date" or termination options for the Cullgen Merger.
• Liquidity Runway: Confirm the company's cash burn rate and whether the $4.1 million cash balance remains sufficient for the 12-month outlook given potential merger delays.
• Asset Monetization Progress: Monitor announcements regarding the sale or licensing of the PUR3100, PUR1800, and PUR1900 assets.
• Shareholder Dilution: Review the final exchange ratio and the resulting ownership percentage for pre-merger Pulmatrix shareholders.
• Going Concern: Assess the likelihood of dissolution or liquidation if the Merger is not consummated and no strategic asset sale is completed.